Mrd As A Prognostic Tool

Michele Cavo, MD, PhD, Bologna University School of Medicine, Bologna, Italy, discusses the applications of measurable residual ...

In this video, Meral Beksac, MD, PhD, Ankara University, Ankara, Turkey, shares some insights into the role of measurable ...

Surbhi Sidana, MBBS Mayo Clinic, Rochester, MN, discusses preliminary data regarding the role of measurable residual disease ...

Morie Gertz, MD, MACP, Mayo Clinic, Rochester, MN, discusses the use of measurable residual disease (

In this video, Krish Patel, MD, Sarah Cannon Research Institute, Nashville, TN, comments on the use of measurable residual ...

In this interview, Saar Gill, MD, PhD, from the University of Pennsylvania, Philadelphia, PA., discusses a retrospective review ...

Luciano Costa, MD, PhD, UAB School of Medicine, Birmingham, AL, discusses measurable residual disease (

Alex Herrera, MD, City of Hope, Duarte, CA, discusses the growing role of circulating tumor DNA (ctDNA) as a validated ...

In this week's video, Dr. Brian G.M. Durie discusses what type of

Measurable residual disease (

Recorded on February 24th as part of the Minimal Residual Disease (

Mattia D'Agostino, MD, University of Turin, Turin, Italy, briefly discusses advances that have been made in the

Dr. Maen Abdelrahim, GI oncologist at Houston Methodist, discusses the

Hervé Avet-Loiseau, MD, PhD from the Cancer Research Center of Toulouse, Toulouse, France discusses his talk on

Luciano Costa, MD, PhD, UAB School of Medicine, Birmingham, AL, discusses the current and future implications of measurable ...

MRD

As part of the 'Challenges in Multiple Myeloma Treatment' session, Noopur Raje, MD, Massachusetts General Hospital, Boston, ...

Alessandro Gozzetti, MD, PhD, Azienda Ospedaliera Universitaria Senese, Siena, Italy, shares an update from the FORTE trial ...

Measurable residual disease (

For the past fifteen years, Lymphoma & Myeloma has been the premier forum on the latest advances in lymphoma, myeloma, and ...